Mount Sinai Receives $1.7 million to Study Natural Killer Cell Dysfunction in Bladder Cancer
The Tisch Cancer Institute Deepens Bladder Cancer Care With New Center of Excellence
The Icahn School of Medicine at Mount Sinai has been awarded nearly $1.7 million in grant funding from the U.S. Department of Defense to study how bladder cancer affects certain types of white blood cells called “natural killer” cells, or NK cells, which control and limit tumor growth. A clinical and research team of investigators with expertise in bladder cancer and immunotherapy will also design interventions to reverse NK cell dysfunction. According to the U.S. Department of Veterans Affairs, bladder cancer is the fourth most common cancer among veterans. Smoking and exposure to industrial chemicals are the leading causes.
The immune system is essential for rapid and efficient tumor surveillance. NK cells are mobilized during early tumor development in order to limit tumor growth, direct the killing of tumor cells, and prevent further growth. However, studies conducted at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai have shown that NK cells found in human bladder cancers are severely compromised. Researchers suspect that cancer cells interfere with the ability of these cells to contain bladder tumor growth.
“With a better understanding of how bladder tumors prevent the functionality of NK cells, we can design therapies to interfere with this processes by using blood cells and tumor tissue from patients with bladder cancer,” said principal investigator Nina Bhardwaj, MD, PhD, Professor of Medicine (Hematology and Medical Oncology) and Director of Immunotherapy at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. Dr. Bhardwaj anticipates clinical trials to begin in one to two years.
This study also addresses risk factors associated with bladder cancer for men and women in uniform. In March 2016, the National Academy of Medicine identified a possible link between bladder cancer and Agent Orange, the herbicide chemical weaponized by the U.S. military during the Vietnam War. Such a link would place veterans who served during the Vietnam conflict at a higher risk than other groups.
“These studies have potential to improve the health and well-being of our active service members, our veterans, and the general public,” said principal investigator John Sfakianos, MD, Assistant Professor of Urology and Urologic Oncology at the Icahn School of Medicine at Mount Sinai. “The ability to detect and reverse NK cell dysfunction in individuals with bladder cancer could also lead to new therapies for patients with other malignancies.”
The study is expected to be completed in three years.
In addition to the study, Mount Sinai is launching a new Center of Excellence for Bladder Cancer to further deepen its commitment to quality care for bladder cancer patients. The co-directors of the center are Matthew Galsky, MD, Director of Genitourinary Medical Oncology at The Tisch Cancer Institute, and Peter Wiklund, MD, PhD, Director of the Bladder Cancer Program of the Mount Sinai Health System.
The Center of Excellence for Bladder Cancer is focused on bringing multi-disciplinary, cutting-edge, and highly personalized care to patients with all forms of bladder cancer. The Center brings together world-class physicians to provide exceptional patient care that draws from our experience, innovation, clinical trials, research, and education.
“The Center of Excellence for Bladder Cancer is part of The Tisch Cancer Institute and uses the most advanced diagnostic and treatment approaches within state-of-the-art facilities,” said Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute, Chair of Oncological Sciences, and Ward-Coleman Professor in Cancer Research of the Icahn School of Medicine at Mount Sinai. “Coordinated care teams include Medical Oncology, Surgical Oncology, Radiation Oncology, and Supportive Oncology, and patients will have broad access to comprehensive supportive services, including social workers, financial counselors, and clergy.”
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.